Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 2 015 DKK -1.52% Market Closed
Market Cap: 129.2B DKK

Genmab A/S
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Genmab A/S
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Cash from Operating Activities
kr1.3B
CAGR 3-Years
33%
CAGR 5-Years
3%
CAGR 10-Years
62%
Zealand Pharma A/S
CSE:ZEAL
Cash from Operating Activities
kr7.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Cash from Operating Activities
-€106.7m
CAGR 3-Years
39%
CAGR 5-Years
14%
CAGR 10-Years
-10%
B
Bavarian Nordic A/S
CSE:BAVA
Cash from Operating Activities
kr3.1B
CAGR 3-Years
N/A
CAGR 5-Years
26%
CAGR 10-Years
14%
Bioporto A/S
CSE:BIOPOR
Cash from Operating Activities
-kr78.9m
CAGR 3-Years
-16%
CAGR 5-Years
-14%
CAGR 10-Years
-18%
Saniona AB
STO:SANION
Cash from Operating Activities
kr650.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genmab A/S
Glance View

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
411.07 DKK
Overvaluation 80%
Intrinsic Value
Price

See Also

What is Genmab A/S's Cash from Operating Activities?
Cash from Operating Activities
1.3B DKK

Based on the financial report for Sep 30, 2025, Genmab A/S's Cash from Operating Activities amounts to 1.3B DKK.

What is Genmab A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
62%

Over the last year, the Cash from Operating Activities growth was 30%. The average annual Cash from Operating Activities growth rates for Genmab A/S have been 33% over the past three years , 3% over the past five years , and 62% over the past ten years .

Back to Top